|
|
Pharmacy Information 2026
抗体寡核苷酸偶联物的研究进展——抗体递送siRNA的可行性分析
|
Abstract:
抗体–寡核苷酸偶联物(AOC)作为新兴的靶向递送平台，通过将单克隆抗体的特异性靶向能力与治疗性寡核苷酸(如siRNA、ASO)的基因调控功能相结合，旨在系统性解决寡核苷酸药物，尤其是siRNA疗法在肝外组织递送中面临的体内不稳定、细胞摄取效率低及内体逃逸困难等核心瓶颈。本文聚焦于siRNA的有效递送及应用，详细阐述了AOC的三大组成部分：决定组织特异性的靶向抗体、执行基因沉默的有效载荷以及控制时空释放的连接子(Linker)，并剖析了其从靶向结合、内吞、内体逃逸到胞内发挥作用的完整递送路径与机制。目前，该领域已从概念验证快速进入临床开发关键期，全球竞争格局初显，代表的生物技术公司主导了针对罕见神经肌肉疾病的领先管线，其中部分候选药物已推进至临床后期。尽管面临内体逃逸效率低、生产工艺复杂等挑战，但AOC平台展现出的模块化设计优势和精准治疗潜力，为其未来拓展至心血管疾病、肿瘤免疫及中枢神经系统疾病等更广阔的治疗领域奠定了坚实基础，标志着精准基因药物治疗新时代的开启。
Antibody-Oligonucleotide Conjugates (AOCs) represent an emerging targeted delivery platform designed to systematically overcome the core challenges associated with oligonucleotide therapeutics, particularly the extrahepatic delivery of siRNA. By integrating the specific targeting capability of monoclonal antibodies with the gene-regulatory function of therapeutic oligonucleotides such as siRNA and ASOs, AOCs address critical bottlenecks including in vivo instability, inefficient cellular uptake, and the difficulty of endosomal escape. This article focuses on the efficient delivery and application of siRNA. It details the three fundamental components of AOCs: the targeting antibody, which confers tissue specificity; the therapeutic payload (e.g., siRNA), which executes gene silencing; and the linker, which controls spatiotemporal release. Furthermore, it dissects the complete delivery pathway and mechanism, encompassing target binding, internalization, endosomal escape, and subsequent intracellular action. The field has rapidly progressed from proof-of-concept to a critical phase of clinical development, with an emerging global competitive landscape. Leading biotechnology companies are driving pipelines focused on rare neuromuscular diseases, some of which have advanced to late-stage clinical trials. Despite persistent challenges such as low endosomal escape efficiency and complex manufacturing processes, the modular design and precise therapeutic potential of the AOC platform lay a solid foundation for its future expansion into broader therapeutic areas. These include cardiovascular diseases, cancer immunotherapy, and central nervous system disorders, heralding the dawn of a new era in precision genetic medicine.
| [1] | Ebenezer, O., Oyebamiji, A.K., Olanlokun, J.O., Tuszynski, J.A. and Wong, G.K. (2025) Recent Update on siRNA Therapeutics. International Journal of Molecular Sciences, 26, Article 3456. https://doi.org/10.3390/ijms26083456 |
| [2] | Pérez-Carrión, M.D., Posadas, I. and Ceña, V. (2024) Nanoparticles and siRNA: A New Era in Therapeutics? Pharmacological Research, 201, Article 107102. https://doi.org/10.1016/j.phrs.2024.107102 |
| [3] | Khan, S., Rehman, U., Parveen, N., Kumar, S., Baboota, S. and Ali, J. (2023) siRNA Therapeutics: Insights, Challenges, Remedies and Future Prospects. Expert Opinion on Drug Delivery, 20, 1167-1187. https://doi.org/10.1080/17425247.2023.2251890 |
| [4] | Tang, Q. and Khvorova, A. (2024) RNAi-Based Drug Design: Considerations and Future Directions. Nature Reviews Drug Discovery, 23, 341-364. https://doi.org/10.1038/s41573-024-00912-9 |
| [5] | Friedrich, M. and Aigner, A. (2022) Therapeutic siRNA: State-of-the-Art and Future Perspectives. BioDrugs, 36, 549-571. https://doi.org/10.1007/s40259-022-00549-3 |
| [6] | Jadhav, V., Vaishnaw, A., Fitzgerald, K. and Maier, M.A. (2024) RNA Interference in the Era of Nucleic Acid Therapeutics. Nature Biotechnology, 42, 394-405. https://doi.org/10.1038/s41587-023-02105-y |
| [7] | Hu, B., Zhong, L., Weng, Y., Peng, L., Huang, Y., Zhao, Y., et al. (2020) Therapeutic siRNA: State of the Art. Signal Transduction and Targeted Therapy, 5, Article No. 101. https://doi.org/10.1038/s41392-020-0207-x |
| [8] | Lv, Z. and Dai, Y. (2025) mRNA Vaccines and siRNAs Targeting Cancer Immunotherapy: Challenges and Opportunities. Discover Oncology, 16, 1-17. https://doi.org/10.1007/s12672-025-03070-5 |
| [9] | Kim, T., Viard, M., Afonin, K.A., Gupta, K., Popov, M., Salotti, J., et al. (2020) Characterization of Cationic Bolaamphiphile Vesicles for siRNA Delivery into Tumors and Brain. Molecular Therapy—Nucleic Acids, 20, 359-372. https://doi.org/10.1016/j.omtn.2020.02.011 |
| [10] | Hazekawa, M., Nishinakagawa, T., Mori, T., Yoshida, M., Uchida, T. and Ishibashi, D. (2021) Preparation of siRNA-PLGA/Fab’-PLGA Mixed Micellar System with Target Cell-Specific Recognition. Scientific Reports, 11, Article No. 16789. https://doi.org/10.1038/s41598-021-96245-3 |
| [11] | Roberts, T.C., Langer, R. and Wood, M.J.A. (2020) Advances in Oligonucleotide Drug Delivery. Nature Reviews Drug Discovery, 19, 673-694. https://doi.org/10.1038/s41573-020-0075-7 |
| [12] | Abosalha, A.K., Ahmad, W., Boyajian, J., Islam, P., Ghebretatios, M., Schaly, S., et al. (2023) A Comprehensive Update of siRNA Delivery Design Strategies for Targeted and Effective Gene Silencing in Gene Therapy and Other Applications. Expert Opinion on Drug Discovery, 18, 149-161. https://doi.org/10.1080/17460441.2022.2155630 |
| [13] | Chernikov, I.V., Ponomareva, U.A. and Chernolovskaya, E.L. (2023) Structural Modifications of siRNA Improve Its Performance in Vivo. International Journal of Molecular Sciences, 24, Article 956. https://doi.org/10.3390/ijms24020956 |
| [14] | Alshaer, W., Zureigat, H., Al Karaki, A., Al-Kadash, A., Gharaibeh, L., Hatmal, M.M., et al. (2021) siRNA: Mechanism of Action, Challenges, and Therapeutic Approaches. European Journal of Pharmacology, 905, Article 174178. https://doi.org/10.1016/j.ejphar.2021.174178 |
| [15] | Zhang, M.M., Bahal, R., Rasmussen, T.P., Manautou, J.E. and Zhong, X. (2021) The Growth of siRNA-Based Therapeutics: Updated Clinical Studies. Biochemical Pharmacology, 189, Article 114432. https://doi.org/10.1016/j.bcp.2021.114432 |
| [16] | Tran, P., Weldemichael, T., Liu, Z. and Li, H. (2022) Delivery of Oligonucleotides: Efficiency with Lipid Conjugation and Clinical Outcome. Pharmaceutics, 14, Article 342. https://doi.org/10.3390/pharmaceutics14020342 |
| [17] | Sehgal, A., Vaishnaw, A. and Fitzgerald, K. (2013) Liver as a Target for Oligonucleotide Therapeutics. Journal of Hepatology, 59, 1354-1359. https://doi.org/10.1016/j.jhep.2013.05.045 |
| [18] | Yu, X., Ma, Z.M., Ji, F., Chen, M. and Baigude, H. (2026) Preparation and in Vitro Functional Validation of a Novel Antibody-siRNA-Exatecan Conjugate (AREC). International Immunopharmacology, 168, Article 115938. https://doi.org/10.1016/j.intimp.2025.115938 |
| [19] | Meng, Q., Yang, M., Xing, F., Xie, Z., Hao, Y., Jiang, P., et al. (2025) Antibody-Oligonucleotide Conjugates in Cancer Therapy: Potential and Promise. Critical Reviews in Oncology/Hematology, 215, Article 104858. https://doi.org/10.1016/j.critrevonc.2025.104858 |
| [20] | Subhan, M.A., Attia, S.A. and Torchilin, V.P. (2021) Advances in siRNA Delivery Strategies for the Treatment of MDR Cancer. Life Sciences, 274, Article 119337. https://doi.org/10.1016/j.lfs.2021.119337 |
| [21] | Cuellar, T.L., Barnes, D., Nelson, C., Tanguay, J., Yu, S.F., et al. (2015) Systematic Evaluation of Antibody-Mediated siRNA Delivery Using an Industrial Platform of THIOMAB-siRNA Conjugates. Nucleic Acids Research, 43, 1189-1203. https://doi.org/10.1093/nar/gku1362 |
| [22] | Malecova, B., Burke, R.S., Cochran, M., Hood, M.D., Johns, R., Kovach, P.R., et al. (2023) Targeted Tissue Delivery of RNA Therapeutics Using Antibody-Oligonucleotide Conjugates (AOCs). Nucleic Acids Research, 51, 5901-5910. https://doi.org/10.1093/nar/gkad415 |
| [23] | Yarian, F., Alibakhshi, A., Eyvazi, S., Arezumand, R. and Ahangarzadeh, S. (2019) Antibody-Drug Therapeutic Conjugates: Potential of Antibody-siRNAs in Cancer Therapy. Journal of Cellular Physiology, 234, 16724-16738. https://doi.org/10.1002/jcp.28490 |
| [24] | Cochran, M., Marks, I., Albin, T., Arias, D., Kovach, P., Darimont, B., et al. (2024) Structure-Activity Relationship of Antibody-Oligonucleotide Conjugates: Evaluating Bioconjugation Strategies for Antibody-Phosphorodiamidate Morpholino Oligomer Conjugates for Drug Development. Journal of Medicinal Chemistry, 67, 14868-14884. https://doi.org/10.1021/acs.jmedchem.4c00803 |
| [25] | Lu, H., Wang, D., Kazane, S., Javahishvili, T., Tian, F., Song, F., et al. (2013) Site-Specific Antibody-Polymer Conjugates for siRNA Delivery. Journal of the American Chemical Society, 135, 13885-13891. https://doi.org/10.1021/ja4059525 |
| [26] | Paunovska, K., Loughrey, D. and Dahlman, J.E. (2022) Drug Delivery Systems for RNA Therapeutics. Nature Reviews Genetics, 23, 265-280. https://doi.org/10.1038/s41576-021-00439-4 |
| [27] | Traber, G.M. and Yu, A. (2024) The Growing Class of Novel RNAi Therapeutics. Molecular Pharmacology, 106, 13-20. https://doi.org/10.1124/molpharm.124.000895 |
| [28] | Bhakta-Yadav, M.S. and Brown, T.L. (2025) Important Aspects of siRNA Design for Optimal Efficacy in Vitro and in Vivo. International Journal of Cell Biology, 2025, Article 6663816. https://doi.org/10.1155/ijcb/6663816 |
| [29] | Li, M., An, H., Zhang, J., Li, W., Yu, C. and Wang, L. (2025) Advances in the Pharmaceutical Development of Antibody-Oligonucleotide Conjugates. European Journal of Pharmaceutical Sciences, Article 107292. https://doi.org/10.1016/j.ejps.2025.107292 |
| [30] | Zhou, X., Han, Y., Fang, Y., Ma, P., Zhou, J., Jiang, Y., et al. (2025) Antibody-Drug Conjugates: Current Challenges and Innovative Solutions for Precision Cancer Therapy. Med, 6, Article 100849. https://doi.org/10.1016/j.medj.2025.100849 |
| [31] | Weeden, T., Picariello, T., Quinn, B., Spring, S., Shen, P., Qiu, Q., et al. (2025) FORCE Platform Overcomes Barriers of Oligonucleotide Delivery to Muscle and Corrects Myotonic Dystrophy Features in Preclinical Models. Communications Medicine, 5, Article No. 22. https://doi.org/10.1038/s43856-025-00733-w |
| [32] | Mullard, A. (2022) Antibody-Oligonucleotide Conjugates Enter the Clinic. Nature Reviews Drug Discovery, 21, 6-8. https://doi.org/10.1038/d41573-021-00213-5 |
| [33] | Johnson, N., Day, J., Hamel, J., Thornton, C., Subramony, S.H., et al. (2024) Initial Results of the Phase 2 Open-Label Extension Study of AOC 1001 in Adults with Myotonic Dystrophy Type 1: MARINA-OLE™. Muscular Dystrophy Association National Office. |
| [34] | 马健, 余同林, 崔帅帅, 等. 寡核苷酸偶联物的研究进展[J]. 药学进展, 2024, 48(8): 565-578. |
| [35] | Etxaniz, U., Marks, I., Albin, T., Diaz, M., Bhardwaj, R., Anderson, A., et al. (2025) AOC 1044 Induces Exon 44 Skipping and Restores Dystrophin Protein in Preclinical Models of Duchenne Muscular Dystrophy. Nucleic Acids Research, 53, gkaf241. https://doi.org/10.1093/nar/gkaf241 |
| [36] | Bäumer, N., Appel, N., Terheyden, L., Buchholz, F., Rossig, C., Müller-Tidow, C., et al. (2016) Antibody-Coupled siRNA as an Efficient Method for in Vivo mRNA Knockdown. Nature Protocols, 11, 22-36. https://doi.org/10.1038/nprot.2015.137 |
| [37] | Shen, L., Wu, Y., Xie, W., Chen, G. and Xing, H. (2023) Chemical Biology Approaches toward Precise Structure Control of IgG-Based Antibody-Oligonucleotide Conjugates. ChemBioChem, 24, e202300077. https://doi.org/10.1002/cbic.202300077 |
| [38] | Harrabi, O., Chen, A., Sangalang, E., Doyle, L., Fontaine, D., et al. (2020) 615 Targeted Immune Cell Activation by Systemic Delivery of Toll-Like Receptor 9 Agonist Antibody Conjugates Induce Potent Anti-Tumor Immunity. |
| [39] | Sheridan, C. (2026) Now with Oligos: Antibody-Oligonucleotide Conjugates Are the New Drug Modality to Watch. Nature Biotechnology, 44, 3-5. https://doi.org/10.1038/s41587-025-02987-0 |
| [40] | 杜慧, 肖宇锋, 张玢. 全球小核酸药物的上市及临床研究现状分析[J]. 中国新药杂志, 2025, 34(12): 1233-1243. |
| [41] | Li, J.H., Liu, L. and Zhao, X.H. (2024) Precision Targeting in Oncology: The Future of Conjugated Drugs. Biomedicine & Pharmacotherapy, 177, Article 117106. https://doi.org/10.1016/j.biopha.2024.117106 |
| [42] | Sesay, M., Bourguignon, N. and Lee, H.I. (2024) Antibody-Oligonucleotide Conjugates Clinical Manufacturing—A New Paradigm Shift of Bio-Conjugates for Therapeutics. |
| [43] | Rady, T., Lehot, V., Most, J., Erb, S., Cianferani, S., Chaubet, G., et al. (2024) Protocol to Generate, Purify, and Analyze Antibody-Oligonucleotide Conjugates from Off-the-Shelf Antibodies. STAR Protocols, 5, Article 103329. https://doi.org/10.1016/j.xpro.2024.103329 |
| [44] | Dovgan, I., Koniev, O., Kolodych, S. and Wagner, A. (2019) Antibody-Oligonucleotide Conjugates as Therapeutic, Imaging, and Detection Agents. Bioconjugate Chemistry, 30, 2483-2501. https://doi.org/10.1021/acs.bioconjchem.9b00306 |
| [45] | Zhou, L., Bi, J., Chang, S., Bai, Z., Yu, J., Wang, R., et al. (2025) Self‐Assembled Antibody‐Oligonucleotide Conjugates for Targeted Delivery of Complementary Antisense Oligonucleotides. Angewandte Chemie International Edition, 64, e202415272. https://doi.org/10.1002/anie.202415272 |
| [46] | Lehot, V., Kuhn, I., Nothisen, M., Erb, S., Kolodych, S., Cianférani, S., et al. (2021) Non-Specific Interactions of Antibody-Oligonucleotide Conjugates with Living Cells. Scientific Reports, 11, Article No. 5881. https://doi.org/10.1038/s41598-021-85352-w |
| [47] | Fu, Z., Li, S., Han, S., Shi, C. and Zhang, Y. (2022) Antibody Drug Conjugate: The “Biological Missile” for Targeted Cancer Therapy. Signal Transduction and Targeted Therapy, 7, Article No. 93. https://doi.org/10.1038/s41392-022-00947-7 |
| [48] | Zhang, D., Duque-Jimenez, J., Facchinetti, F., Brixi, G., Rhee, K., Feng, W.W., et al. (2025) Transferrin Receptor Targeting Chimeras for Membrane Protein Degradation. Nature, 638, 787-795. https://doi.org/10.1038/s41586-024-07947-3 |
| [49] | Sugo, T., Terada, M., Oikawa, T., Miyata, K., Nishimura, S., Kenjo, E., et al. (2016) Development of Antibody-siRNA Conjugate Targeted to Cardiac and Skeletal Muscles. Journal of Controlled Release, 237, 1-13. https://doi.org/10.1016/j.jconrel.2016.06.036 |
| [50] | Barker, S.J., Thayer, M.B., Kim, C., Tatarakis, D., Simon, M.J., Dial, R., et al. (2024) Targeting the Transferrin Receptor to Transport Antisense Oligonucleotides across the Mammalian Blood-Brain Barrier. Science Translational Medicine, 16, eadi2245. https://doi.org/10.1126/scitranslmed.adi2245 |
| [51] | Dugal-Tessier, J., Thirumalairajan, S. and Jain, N. (2021) Antibody-Oligonucleotide Conjugates: A Twist to Antibody-Drug Conjugates. Journal of Clinical Medicine, 10, Article 838. https://doi.org/10.3390/jcm10040838 |
| [52] | Zhao, Y., Jiang, H., Yu, J., Wang, L. and Du, J. (2023) Engineered Histidine-Rich Peptides Enhance Endosomal Escape for Antibody-Targeted Intracellular Delivery of Functional Proteins. Angewandte Chemie International Edition, 62, e202304692. https://doi.org/10.1002/anie.202304692 |
| [53] | Jiao, J., Qian, Y., Lv, Y., Wei, W., Long, Y., Guo, X., et al. (2024) Overcoming Limitations and Advancing the Therapeutic Potential of Antibody-Oligonucleotide Conjugates (AOCs): Current Status and Future Perspectives. Pharmacological Research, 209, Article 107469. https://doi.org/10.1016/j.phrs.2024.107469 |
| [54] | Allen, R. and Yokota, T. (2024) Endosomal Escape and Nuclear Localization: Critical Barriers for Therapeutic Nucleic Acids. Molecules, 29, Article 5997. https://doi.org/10.3390/molecules29245997 |
| [55] | Yin, W. and Rogge, M. (2019) Targeting RNA: A Transformative Therapeutic Strategy. Clinical and Translational Science, 12, 98-112. https://doi.org/10.1111/cts.12624 |
| [56] | Tripathy, R.K. and Pande, A.H. (2025) Nanobody-Oligonucleotide Conjugates (NucleoBodies): The Next Frontier in Oligonucleotide Therapy. Pharmaceutical Research, 42, 219-236. https://doi.org/10.1007/s11095-025-03829-z |
| [57] | Karamanlidis, G., Malecova, B., Cochran, M., Kovach, P.R., Doppalapudi, V.R., Huang, H., et al. (2024) Cardiac Delivery of RNA Therapeutics Using Antibody-Oligonucleotide Conjugates (AOCs) for Treating Genetic Cardiomyopathies. Journal of Cardiac Failure, 30, S11. https://doi.org/10.1016/j.cardfail.2024.08.020 |
| [58] | Murphy, A., Hill, R. and Berna, M. (2024) Bioanalytical Approaches to Support the Development of Antibody-Oligonucleotide Conjugate (AOC) Therapeutic Proteins. Xenobiotica, 54, 552-562. https://doi.org/10.1080/00498254.2024.2339983 |
